0

First Quarter 2013

Earnings Presentation

Dr. Ge Li, Chairman and CEO

Edward Hu, COO/CFO

1

Cautionary Note Regarding Forward-Looking Statements

This presentation contains "forward-looking statements” within the meaning of the

Private Securities Litigation Reform Act of 1995. Forward-looking statements are

not historical facts, but instead are predictions about future events. Examples of

forward-looking statements in this presentation include statements about our

second-quarter and full-year 2013 guidance, the goals of our various service

offerings and the prospects of our strategic partnerships. Although we believe that

our predictions are reasonable, future events are inherently uncertain and our

forward-looking statements may turn out to be incorrect. Our forward-looking

statements are subject to risks relating to, among other things, our ability to

increase volume for our chemistry service offerings, to meet timelines for the

expansion of our biologics service offerings, to realize the anticipated benefits of

our strategic partnerships, to protect our clients’ intellectual property and to

compete effectively. Additional information about these and other relevant risks can

be found in our Annual Report on Form 20-F for the year ended December 31,

2012. The forward-looking statements in this presentation speak only on the date

that they are made, and we assume no obligation to update any forward-looking

statements except as required by law.

2

Use of Non-GAAP and Pro-Forma Financial Measures

We have provided the first-quarter 2012 and 2013 gross profit, gross

margin, operating income, operating margin, net income, net margin, and

earnings per ADS on a non-GAAP basis, which excludes share-based

compensation expenses and the amortization and deferred tax impact of

acquired intangible assets. We believe both management and investors

benefit from referring to these non-GAAP financial measures in assessing

our financial performance and liquidity and when planning and forecasting

future periods. These non-GAAP operating measures are useful for

understanding and assessing underlying business performance and

operating trends. We expect to continue to provide net income and

earnings per ADS on a non-GAAP basis using a consistent method on a

quarterly basis.

You should not view non-GAAP results on a stand-alone basis or as a

substitute for results under GAAP, or as being comparable to results

reported or forecasted by other companies, and should refer to the

reconciliation of GAAP measures to non-GAAP measures for the indicated

periods attached hereto.

3

Overview

We are achieving double-digit, broad-based revenue growth, led by

China-based Laboratory Services and research manufacturing

Commercial manufacturing is building a pipeline of products to

reaccelerate growth in 2014 and beyond

We are effectively controlling our costs with strategies such as our

Wuhan chemistry facility and our Lean Sigma programs

By continuing to control our costs, we expect to maintain flat year-

over-year margins throughout 2013

As a result of our revenue growth and progress on margins, we are

reconfirming our full-year 2013 revenue and EPS guidance

4

Overview

We continue to invest in capabilities and capacity across our

business units to sustain strong revenue and earnings growth

Our free cash flow is growing substantially, and we plan to return

much of it to shareholders through share purchases

To leverage our partners’ knowledge and experience, we are entering

into strategic partnerships to create more long-term value, such as

our JVs with MedImmune for novel biologics development in China

and with PRA for clinical trial services in China

5

First-Quarter 2013 Performance Versus Guidance

Actual Guidance

Total Revenues $131.9 million $129-131 million

GAAP Diluted EPS $0.30 $0.26-$0.27

NonGAAP Diluted EPS $0.35 $0.31-$0.32

We exceeded our revenue guidance for the quarter mainly due to

better than expected performance by Manufacturing Services

We exceeded our EPS guidance for the quarter as a result of better

revenues, improvements in operational efficiency, and a $1.2 million

mark-to-market gain on foreign exchange forward contracts

6

First-Quarter 2013 Revenue Summary

(US$ in millions)

First Quarter

2013 2012 Δ

Total Net Revenue $131.9 $118.0 11.7%

China-Based Laboratory Services $74.5 $64.4 15.5%

U.S.-Based Laboratory Services $23.0 $22.2 3.8%

Total Laboratory Services $97.5 $86.6 12.5%

Manufacturing Services $34.4 $31.4 9.6%

7

Total Net Revenues

(US$ in Millions)

1Q12 2Q12 3Q12 4Q12 1Q13

Manufacturing

Services

China-Based

Laboratory

Services

Revenue Performance by Service

U.S.-Based

Laboratory

Services

$118.0

22.2

64.4

31.4

$130.4

70.3

23.3

36.8

77.0

21.9

26.9

$125.8

81.5

22.3

21.9

$125.7

74.5

23.0

34.4

$131.9

Overall, the company achieved

record revenues and double-

digit year-over-year revenue

growth in the first quarter

China-based Laboratory

Services experienced its typical

sequential decline in first-

quarter revenues and strong

year-over-year growth

U.S.-based Laboratory Services

achieved steady, but modest

growth in a more mature

market

Manufacturing Services

benefited from strong

sequential growth in both

research and commercial

manufacturing

8

First-Quarter 2013 GAAP Financial Summary

(US$ in millions)

First Quarter

2013 2012 %

Growth

Net Revenue $131.9 $118.0 11.7%

Gross Profit 47.4 41.9 13.2%

Gross Margin 36.0% 35.5%

Operating Income 23.0 20.6 11.4%

Operating Margin 17.4% 17.5%

Net Income 21.7 21.0 3.4%

Effective Tax Rate 20.8% 16.3%

Weighted Average ADS Outstanding—Diluted 71,915,069 74,543,632 (3.5%)

Diluted Net Earnings Per ADS 0.30 0.28 7.2%

9

(US$ in Millions)

1Q12 2Q12 3Q12 4Q12 1Q13

Gross

Profit/

Margin

Revenues

Operating

Income/

Margin

GAAP Revenues/Gross Profit/Operating Income

$118.0

20.6

41.9 35.5%

17.5%

$130.4

46.5

23.8

35.7%

18.2%

$125.8

21.5

46.1 36.6%

17.0%

$125.7

23.6

48.8 38.8%

18.7% 23.0

47.4

$131.9

36.0%

17.4%

Aside from one-time

benefits in 4Q12,

1Q13 margins were

generally in line with

those of prior

quarters

We expect flat year-

over-year GAAP

gross margin and

operating margin in

2013

10

First-Quarter 2013 Non-GAAP* Financial Summary

*Excludes the impact of share-based compensation expenses and amortization and the

deferred tax impact of acquired intangible assets in both periods

(US$ in millions)

First Quarter

2013 2012 %

Growth

Net Revenue $131.9 $118.0 11.7%

Gross Profit 48.6 43.5 11.6%

Gross Margin 36.8% 36.8%

Operating Income 26.7 24.3 9.8%

Operating Margin 20.2% 20.6%

Net Income 25.4 24.5 3.7%

Weighted Average ADS Outstanding—Diluted 71,915,069 74,543,632 (3.5%)

Effective Tax Rate 18.5% 14.9%

Diluted Net Earnings Per ADS 0.35 0.33 7.5%

11

(US$ in Millions)

1Q12 2Q12 3Q12 4Q12 1Q13

Gross

Profit/

Margin

Revenues

Operating

Income/

Margin

Non-GAAP Revenues/Gross Profit/Operating Income

24.3

43.5

$118.0

36.8%

20.6%

$130.4

21.0%

36.8% 48.0

27.4

$125.8

26.6

47.6 37.8%

21.2%

$125.7

50.0

27.4 21.8%

39.8%

$131.9

48.6

26.7

36.8%

20.2%

We also expect flat

year-over-year non-

GAAP gross margin

and operating margin

in 2013

12

Factors Impacting First Quarter 2013 Diluted Earnings Per ADS

$0.28 $0.30

$.06 ($.01)

($.02)

1Q12

Diluted EPS 1Q13

Diluted EPS

Foreign

Exchange

Business

Growth Investment* Share

Purchases

Labor

Inflation

$.01

* Investment includes losses from biologics R&D, biologics manufacturing facilities, JVs with

MedImmune and risk sharing projects

$0.33 $0.35

GAAP

Non-GAAP Non-GAAP

GAAP ($.02)

13

Capital Resources and Cash Flow

Cash and short-term investments of $265.7 million at March

31, 2013

Total debt of $67.9 million at March 31, 2013

Operating cash flow of $39.4 million for first-quarter 2013

Capital expenditures of $6.0 million for first-quarter 2013; we

continue to expect full-year capital expenditures of about

$60 million

14

(US$ in Millions)

Capital

Expend-

itures

Operating

Cash

Flow

Free

Cash

Flow

Cash Flow and Share Purchases

$101.1

$131.0

$63.9

$37.1

$67.8

$63.2

Cash Flow Share Purchases

$67.0

$100.0

2012 2012 3/2013-

3/2015

Est.

2011

While making the

investments necessary

to sustain business

growth, we are

returning much of our

free cash flow to

investors

15

We Reconfirm Full-Year 2013 Financial Guidance

Total revenues of $565-$575 million, up 13-15% year

over year

GAAP and non-GAAP gross margin and operating

margin comparable to those in 2012 (new guidance)

GAAP diluted earnings per ADS of $1.26-$1.30, up 6-9%

Non-GAAP diluted earnings per ADS of $1.49-$1.53, up

6-9%

Capital expenditures of about $60 million

16

Second-Quarter 2013 Preview

Estimated total revenues of $138-$140 million

Estimated GAAP and Non-GAAP diluted earnings per ADS of

$0.34-$0.35 and $0.39-$0.40, respectively

Accelerating year-over-year revenue growth in the second half

of 2013 across several business units

17

First-Quarter 2013 Revenue Distribution by Service Offering

1Q12 1Q13

Manufacturing

26.6%

Development**

9.0%

U.S. Lab

Services

17.5%

U.S. Lab

Services

18.8%

Medicinal

Chemistry

And Other

Discovery*

27.3%

Synthetic

Chemistry

18.3%

Manufacturing

26.1%

Development**

13.2%

Medicinal

Chemistry

And Other

Discovery*

26.0%

Synthetic

Chemistry

17.2%

*Includes Medicinal Chemistry, Biology, DMPK/ADME, Biological Reagents and others

**Includes Formulation, Analytical Development, Toxicology, Bioanalytical Services, Biologics,

Clinical, and Genomics

China-Based

Lab Services

18

Synthetic Chemistry

This business (17% of total company revenue now) is

becoming commoditized, with competition from many Chinese

CROs causing pricing pressure

Our advantages of scale and experience will allow us to

achieve single-digit revenue growth in this business in 2013

Our Lean Sigma programs have resulted in significant

improvement in operating efficiency and cost savings

Synthetic chemistry work is increasingly being done at our new

Wuhan facility, which has relatively lower operating costs and

offers customers another pricing option

19

Medicinal Chemistry and Other Drug Discovery Services

We expect mid-teen revenue growth and stable profitability in

2013, driven by volume growth and improving productivity

New opportunities are available in medicinal chemistry

programs serving Chinese pharmaceutical clients

We expect substantial revenue and profit growth this year in

biology, where WuXi is building a leading technology platform

in oncology, infectious disease, CNS, and other areas

20

Toxicology

Our toxicology business is growing well despite the

worldwide slump in this business

We are the #1 toxicology CRO in China

We more than doubled annual revenues in 2012 and are

targeting an increase of more than 40% in revenues in 2013;

more than 30% of revenues are from domestic Chinese

clients

This business is now profitable, and profitability will improve

with increasing capacity utilization

Our Suzhou site is currently at about 60% capacity; we

expect to reach optimum (~80-85%) capacity by year end and

will consider building out the remaining shell space within

the existing facility next year

21

Biologics Services Overview

WuXi is the partner of choice for biologics services in China, as few CROs or

pharmaceutical companies have biologics facilities here

Chinese regulations require that biologics used in clinical trials either be approved in

other markets or manufactured in China

Our project portfolio is mostly novel molecules with some biosimilars from both

multinational and Chinese customers

We have built a highly capable team of about 350 people, including about 30 returnees

with US/EU industry experience

We made about $30 million in capital expenditures through the end of 2012, including

construction of discovery and development laboratories in Shanghai and a cGMP drug

substance manufacturing facility in WuXi in 2012, and we plan $16-$18 million more in

capital expenditures in 2013 to build out a fill/finish facility and purchase lab equipment

We plan to install 2,000 L bioreactors in the second half of 2013 that will enable us to

produce Phase 3 clinical trial materials

We continue to ramp up revenues with increasing numbers of projects; backlog totals

about $40 million as of the end of March; we are serving about 50 customers worldwide

22

Strategic Partnerships in Drug Development

While WuXi will remain predominantly a CRO, we will help our

partners to develop and commercialize innovative products in

China

Some current medicinal chemistry projects earn bonuses for

success in return for lower FTE rates

Joint venture with MedImmune will develop and commercialize

MEDI5117 for treating rheumatoid arthritis and other

autoimmune diseases in China

Joint venture with PRA will offer a broad platform of Phase 1-4

clinical trial services in China, Hong Kong and Macau

Some biologics contracts include milestone payments and/or

single-digit royalties

23

U.S.-Based Laboratory Services

First-half revenue growth is expected to be slower, due to lower

demand in biologics testing and difficult comparisons caused

by strong growth in the first half of 2012

Second-half growth is expected to be stronger

Profitability continues to improve

We continue to expect broad-based, high-single-digit revenue

growth, with stable margins, in this business in the long term

24

Small Molecule Manufacturing Services

Overall small molecule manufacturing revenue to grow at mid-

teen rate in 2013, driven by strong growth in research

manufacturing

Commercial manufacturing revenue will be relatively flat year-

over-year in 2013 as we continue to diversify our portfolio

beyond one large product

We currently manufacture advanced intermediates for six

commercial products

We also manufacture supplies (intermediates and APIs) of

seven additional products currently in Phase 3, including some

with large commercial revenue potential for WuXi

25

Building Our Capabilities Will Drive Growth

Continued revenue growth across China-based Laboratory

Services, driven by our ability to deliver high-quality services and

drug candidates for our customers

Increasing utilization of our integrated drug development services

for API manufacturing, IND-enabling toxicology studies and IND

filings with the China SFDA and global regulatory authorities

Continuing growth in Manufacturing Services driven by research

manufacturing and, beginning in 2014, a growing commercial-

manufacturing pipeline

Ramp-up of biologics drug discovery, development, and

manufacturing services

Expansion of our clinical development platform with the WuXi/PRA

joint venture

26

Appendix

GAAP to Non-GAAP Reconciliation

Share Count Information

ADS Shares for Earnings-per-ADS Calculation

27

1Q2013

(US$ in millions)

GAAP

Share-Based

Compensation

Expenses

Amortization of

Acquired Intangible

Assets and Deferred

Tax Impact

Non-GAAP

Net revenues 131.9 131.9

Cost of revenues (84.5) 1.0 0.1 (83.4)

Selling & marketing expense (3.9) (3.9)

General & administrative expense (18.2) 2.6 (15.6)

Research & development expense (2.3) (2.3)

Other income/(exp.), net 4.4 4.4

Income tax expense (5.7) (5.7)

Net income 21.7 3.6 0.1 25.4

First-Quarter 2013 GAAP to Non-GAAP Reconciliation

28

Share Count Information

(As of March 31, 2013)

ADS Shares

ADS issued and outstanding 70,961,529

Share options and equivalents granted and outstanding 2,986,228

ADS available for future grants under employee incentive plan 3,806,752

29

ADS Shares for Earnings-per-ADS Calculation

Date Activities

Weighted

Average ADS

Shares

January 1, 2013 Ordinary share balance1 67,794,840

January 1, 2013 RSUs vested and not exercised 2,345,285

First Quarter 2013 Share options exercised and RSUs vested 229,413

First Quarter 2013 Share repurchase program (922)

March 31, 2013 ADSs outstanding – basic 70,368,616

March 31, 2013 Share options and equivalents 1,546,453

March 31, 2013 ADSs outstanding – diluted 71,915,069

1 542,358,719 ordinary shares, with each ADS representing eight ordinary shares